CONSIDERATIONS FOR OVERACTIVE BLADDER (OAB): FROM DIAGNOSIS TO FOLLOW-UP

Adapted from the Canadian Urology Association Guidelines and developed in association with a multidisciplinary panel of your peers:

- Dr. Greg Bailly
- Dr. Jeff Habert
- Dr. Richard Baverstock
- Dr. Stephen Steele
- Dr. Lysanne Campeau

OAB Overview

OAB is characterized by urinary urgency, with or without urgency urinary incontinence (UUI), often accompanied by frequency and nocturia. Since it is not life-threatening, its impact on quality of life (QOL) plays a significant role in the decision to treat patients.¹

What Is OAB?

The key symptoms of OAB are FUN:1

Frequency

Urgency
(with or without UUI)

Nocturia

Who is impacted?

In Canada, a survey indicated that OAB affects more than: 1.2*





18% overal

Although the prevalence of OAB symptoms increases with age in both sexes, **OAB** is not a normal part of aging.¹

How could OAB affect patients?

According to the Canadian Urological Association (CUA), OAB is associated with a negative impact on:¹

- Q0L
- Older persons with multiple comorbidities
- Work productivity



30% of patients with OAB have depression¹



Urological symptoms are associated with an increased risk of falls, fractures, and hospitalizations¹



Economic burden due to decreased workplace productivity related to OAB¹


^{*} A computer-assisted telephone interview system survey of 3,249 Canadians, 35 years of age or older. 1,2



Many patients are reluctant to start a discussion about OAB.^{1,3} If you detect symptoms, ask probing questions to uncover evidence of FUN.

IDENTIFYING OAB IN YOUR PRACTICE

Get the conversation started: Taking a patient history





50 Y.O. FEMALE

- 5 years of urinary frequency
- Now in new work environment with recent issue of urinary urgency (bathroom proximity issue; had a few embarrassing accidents)

Previouslytreated patient

Discontinued treatment due to:

- Poor tolerability due to side effects (dry mouth and constipation)
- Perceived lack of efficacy
- Type 2 diabetes mellitus (2 years, under control)
- Overweight (BMI 27.1 kg/m²)

Hysterectomy in early 40s due to endometriosis

- Metformin
- DPP-4i
- AM: 2 mugs of coffee (~500 ml)
- Noon: A diet soda (355 ml)
- PM: 3-4 tall cans of dry cider (455 ml) per week + glass of water (250 ml)

RED FLAGS



Is it OAB or an alternative pathology if you observe:1,4

- Hematuria
- Increasing incontinence
- Abnormal digital rectal exam (DRE)
- Neurological disorders (e.g., Parkinson's disease, multiple sclerosis) + voiding dysfunction

Putting the pieces together: Making the diagnosis

65 Y.O. MALE				
Perform clinical examinations ^{1,4,5}	Differentiate symptoms ^{1,4}			
 Abdominal exam (rule out distended bladder) Examine urethral meatus and foreskin tightness (rule out obstruction) DRE (rule out BPE or possible prostate cancer) PSA testing (if appropriate) Urinalysis (rule out UTI) 	BPE Voiding difficulty (hesitancy, intermittent/poor flow)	OAB FUN		
EXAMPLES OF PATIENT COMPLAINTS	"I have a slow stream and find it hard to get started"	"I need to run to the bathroom a dozen times a day, and 2–3 times a night"		

50 Y.O. FEMALE				
Perform clinical examinations ^{1,4,5}	Differentiate symptoms ^{1,4}			
 Abdominal exam (rule out distended bladder) Pelvic exam (assess vagina for prolapse, pelvic floor support, tissue quality/sensation) Urinalysis (rule out UTI and glucosuria) 	Dry OAB	Wet OAB	SUI	
	Urgency and frequency with or without nocturia		Loss of urine associated with physical activity	
	Without UUI	With UUI	p.,,ooa. count,	
EXAMPLES OF PATIENT COMPLAINTS	"I can't sit through a movie without needing the bathroom"	"I couldn't get to the bathroom in time and had an accident"	"I wish I didn't leak urine when I cough, sneeze, or exercise"	

NAVIGATING OAB TREATMENT OPTIONS: WHAT TO CHOOSE AND W

First-line therapies

1. Patient education

Establishing a realistic OAB treatment plan according to patients' expectations is <u>crucial</u> to first-line therapy adherence and compliance. Emphasize that 8–12 weeks of therapy is often required before its effects are obvious to the patient.¹

2. Lifestyle changes



FLUID INTAKE MANAGEMENT¹

- Use bladder diary to establish baselines and assess/monitor treatment outcomes
- Reduce consumption of bladder irritants (caffeine, alcohol, nicotine, and carbonated drinks)



DIETARY MODIFICATION¹

Reduce consumption of foods that are high in sugar, aspartame, fat, and/or spicy



WEIGHT MANAGEMENT¹

- Refer to the new Canada's Food Guide for healthy eating suggestions
- Integrate exercise appropriate for patient's ability (e.g., walking, yoga, swimming)

3. Behavioural therapy



BLADDER TRAINING¹ Different studies demonstrate that bladder training is more effective in symptom control than not providing physical behavioural therapy.

- Timed voiding: voiding at regular intervals has been shown to have beneficial results in comparison to standard care
- Urgency control and suppression: performing general relaxation can decrease intensity and urgency, therefore delaying the voiding process



PELVIC FLOOR MUSCLE TRAINING (PFM; ALSO KNOWN AS KEGELS)¹

- Ask patient to imagine passing of gas without tensing muscles in legs, buttocks, and abdomen
- Incorporate into daily activities to promote compliance and adherence
- Consider referring your patient to a PFM therapist for further instruction

All first-line therapies listed above can be considered in both patient cases. Lifestyle changes involving modifications of fluids/caffeine intake, weight control, dietary modifications, management of bowel regularity, and optimization of other comorbidities may be an effective option in certain cases.

Second-line therapies*

Class	Drugs	MOA	Receptor
Antimuscarinic (AM)¹	 Oxybutynin (IR, TDS, ER) Tolterodine (IR, ER) Darifenacin Trospium Solifenacin Propiverine Fesoterodine 	 Inhibits muscarinic receptors Prohibits detrusor muscle contraction Receptors located throughout the body 	 Blocks M2 and M3 receptors to decrease afferent signals to the bladder May affect other muscarinic receptors
Beta-3 agonist ¹	 Mirabegron 	 Activation causes detrusor muscle relaxation Increases bladder capacity Receptors localized to the bladder 	Acts on beta-3 receptors in bladder

^{*} Comparative clinical significance is unknown.

ER, extended release; IR, immediate release; MOA, mechanism of action; TDS, transdermal patch.

What are your next steps for the two patient cases presented? What factors influence your decision?

Check with your local pharmacist to see what is covered in your province and ask your patients if they have private coverage.

Third-line therapies

Consider referring the patient to a specialist for these therapies:

- Sacral neuromodulation (SNM)
- Intravesical onabotulinumtoxinA injections

SUMMARY OF CONSIDERATIONS FOR SECOND-LINE OAB TREATMENT¹

Start with the lowest recommended dose of an AM **or** a beta-3 agonist

To optimize the dose for the best clinical outcome, try increasing the dose while routinely monitoring for ADEs

If the initial selection is intolerable/ineffective, try an alternative medication with a different MOA

ADE, adverse drug events.

Follow-up

- Ascertain compliance, efficacy, and adverse events/side effects using validated OAB-specific instruments
- Encourage patients to create realistic treatment goals based on their expectations
- If management is deemed ineffective or intolerable, then alternative treatment options should be presented, including drug dose-modification, change within drug class, change of drug class, or consideration of third-line OAB therapies

TROUBLESHOOTING

The male patient

When a male patient presents with both voiding and urine storage symptoms, a possible diagnosis may be...

LUTS secondary to BPE (voiding and storage symptoms) ^{1,5}			
Voiding symptoms		Storage symptoms	
 Interrupted stream Hesitancy Straining Terminal dribbling Feeling of incomplete emptying 	+	 Frequency Urgency With or without urgency urinary incontinence Nocturia 	



Refer to the <u>Resources section</u> for validated and simplified questionnaires that may be used to aid diagnosis.

Special considerations for frail and older persons



POLYPHARMACY

The risk of AEs increases exponentially with each additional medication



AGE-RELATED EFFECTS ON PHARMACOLOGY

- Changes in pharmacokinetics, absorption, distribution, and metabolism
- Reduced drug clearance
- Blood brain barrier dysfunction and cognitive impairment are also of concern in frail and older persons

Patient motivation and counselling tips

Given the impact of OAB on patient psychological well-being and daily activities, it is important to be a source of encouragement throughout your patients' treatment journeys.



Ensure your patients are invested in their goals and their treatment plan—emphasize they are in control



Manage your patients' expectations about the effects medication and lifestyle changes can have



Collaborate with your patients to create realistic goals that can fit into their day-to-day lives



Show involvement in their care—discuss their concerns, celebrate milestones, and follow up frequently

SUMMARY



OAB has an impact on the psychological well-being and day-to-day activities of patients



Barriers to treatment include symptoms of OAB being mistaken as a natural part of aging and patient hesitancy to raise concerns to family physicians



Lifestyle changes—such as diet modification, bladder training, and fluid management—and patient education form the foundation of OAB management



Prescription medications are available for use if behavioural changes are not effective



If lifestyle changes and medications are unsuccessful, patients can be referred to a specialist to receive third-line treatments



Patients with OAB may benefit from support, encouragement, and frequent follow-up from their healthcare team

This newsletter was developed in collaboration with Astellas. Any references to products or treatment options should not be taken as an endorsement or recommendation.

References:

- 1. Corcos J, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142-E173.
- 2. Corcos J, et al. Prevalence of overactive bladder and incontinence in Canada. Can J Urol. 2004;11(3):2278-2284.
- 3. Filipetto FA, et al. The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice. 2014;15(1):96.
- 4. Barkin J, et al. The practical update for family physicians in the diagnosis and management of overactive bladder and lower urinary tract symptoms. *Can J Urol.* 2017;24(5s1):1-11.
- 5. Nickel JC, et al. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J. 2018;12(10):303-312.









RESOURCES

Useful links

Canada's Food Guide

www.food-guide.canada.ca/en/

Behavioural therapy guide

www.canadiancontinence.ca/EN/treatment.php

Bladder diary example

www.niddk.nih.gov/-/media/Files/Urologic-Diseases/diary_508.pdf

Validated questionnaires

OAB-q

www.bmj.com/content/suppl/2012/04/17/bmj.e2365.DC1/mars000342.w2_default.pdf

I-PSS (for men)

www.urospec.com/uro/Forms/ipss.pdf

Some considerations for diagnosing OAB4

Questions	Diagnosis to consider if answer is "yes"
Do you get sudden urges to go to the bathroom that are so strong you cannot ignore them?	OAB
Do you go to the bathroom more than 8 times in a 24-hour period?	OAB
Do you get up 2 or more times during the night to go to the bathroom, and void small volumes?	OAB
Do you have uncontrollable urges to urinate, which sometimes lead to wetting accidents?	UUI
Do you leak urine on the way to the bathroom?	UUI
Do you leak urine when you laugh, sneeze, or lift something?	SUI
Do you use absorbent pads to keep from wetting your clothes?	UUI or SUI
Do you have a slow stream, hesitance, dribbling, or (for men) spraying?	BPE